Map Home
Type / to search with text or keywords
/
keyboard shortcut: Type "/" on your keyboard for a quick search
Search button
Loading...
Loading...
Scroll left
Grants
Citations
H-Index
Patents
News
Books
Scroll right
Collapse sidebar
Data issues & feedback
Adjust height of sidebar
KMap
Grant
Adjust height of sidebar
KMap
Grant
A Phase 3, Randomized, Open-label Study of MK-5684 versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed O
Sponsored by Merck Sharp & Dohme Corp.
Active
$2.2M Funding
6 People
External
Related Topics
prostate cancer,
clinical trial,
treatment comparison,
metastatic cancer,
hormone therapy
People
Brianna Denton
(CD)
Cancer Center Division
﹒Research Compliance Manager I
Carly Deal
(CD)
College of Medicine - Tucson
﹒Clinical Research Coordinator II
Bryan Clines
(CD)
Cancer Center Division
﹒Research Compliance Administrator III
Edward Gelmann
Co-Investigator (COI)
Medicine
﹒Professor
Patricia Robles Quihuis
(CD)
Cancer Center Division
﹒Research Nurse III
Jaron Solsky
(CD)
Cancer Center Division
﹒Clinical Research Manager I
